{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T04:54:28Z","timestamp":1791176068836,"version":"4.1.0"},"update-to":[{"DOI":"10.1002\/14651858.cd007166","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2010,7,7]],"date-time":"2010-07-07T00:00:00Z","timestamp":1278460800000}}],"reference-count":170,"publisher":"Wiley","issue":"7","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd007166.pub2","type":"journal-article","created":{"date-parts":[[2010,6,29]],"date-time":"2010-06-29T20:44:52Z","timestamp":1277844292000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson\u00b4s disease patients with motor complications"],"prefix":"10.1002","volume":"2010","author":[{"given":"Rebecca","family":"Stowe","sequence":"first","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Ives","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl E","family":"Clarke","sequence":"additional","affiliation":[{"name":"College of Medicine and DentalSciences; School of Clinical and Experimental Medicine; University of Birmingham Edgbaston Birmingham West Midlands UK B18 7QH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Deane","sequence":"additional","affiliation":[{"name":"University of East Anglia; Edith Cavell Building; Norwich UK NR4 7TJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"van Hilten","sequence":"additional","affiliation":[{"name":"Leiden University of Medical Center; Department of Neurology; Albinusdreef 2 Leiden Netherlands 2333 ZA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith","family":"Wheatley","sequence":"additional","affiliation":[{"name":"University of Birmingham; Cancer Research UK Clinical Trials Unit, School of Cancer Sciences; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Gray","sequence":"additional","affiliation":[{"name":"The University of Birmingham; Clinical Trials Unit; Robert Aitken Institute for Clincial Research College of Medical Sciences Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Handley","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Furmston","sequence":"additional","affiliation":[{"name":"University of Birmingham; Birmingham Clinical Trials Unit; Edgbaston Birmingham UK B15 2TT"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,7]]},"reference":[{"key":"10.1002\/14651858.CD007166.pub2-BIB0001|cit1","unstructured":"Brooks DJ Kuoppamaki M Vahteristo M Entacapone decreases axial symptoms and tremor in levodopa-treated Parkinson's disease patients experiencing wearing-off symptoms Movement Disorders 2005 S120 (P405)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0002|cit2","unstructured":"Deuschl G Poewe W Poepping M and the Celomen Study Group Efficacy and safety of entacapone as an adjunct to levodopa treatment in Parkinson's disease (PD): Experience from the Austrian-German six months study Parkinsonism and Related Disorders 1999 S75 (P-TU-100)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0003|cit3","unstructured":"Poewe W Deuschl G and Celomen Study Group The effect of entacapone in patients with Parkinson's disease (PD): An Austrian-German long-term multicentre study (Celomen Study) European Journal of Neurology 1999 78 (P194)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0004|cit4","unstructured":"Poewe W Deuschl G Kultalahti E-R Haapaniemi H Leinonen M Reinikainen K Gordin A The efficacy and tolerability of entacapone used in combination with controlled release levodopa preparations in patients with Parkinson's disease Parkinsonism and Related Disorders 2001 S66 (P-TU-221)"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1034\/j.1600-0404.2002.1o174.x","article-title":"Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: A 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen Study)","volume":"105","author":"Poewe","year":"2002","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0006|cit6","unstructured":"Reichmann H on behalf of the ComQol Study Group Efficacy of combining levodopa with entacapone on activities of daily living and quality of life in parkinsonian patients experiencing 'wearing-off' type complications Movement Disorders 2004 S255 (P729)"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1600-0404.2004.00363.x","article-title":"Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations","volume":"111","author":"Reichmann","year":"2005","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0008|cit8","unstructured":"Myllyla VV and the Filomen Study Group Long-term safety of entacapone as an adjunct to levodopa in non-fluctuating and fluctuating patients with Parkinson's disease Movement Disorders 1998 294 (P5.058)"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1046\/j.1468-1331.2001.00168.x","article-title":"Twelve-month safety of entacapone in patients with Parkinson's disease","volume":"8","author":"Myllyla","year":"2001","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0010|cit10","unstructured":"Fenelon G Bourdeix I Pere J-J Galiano L Schadrack J Entacapone provides additional symptomatic benefits in Parkinson's disease patients treated with L-dopa and a dopamine agonist who are experiencing wearing-off motor fluctuations: Results of a randomized, double-blind study Neurology 2002 A466, A467 (P06.102)"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s00702-002-0799-z","article-title":"Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study","volume":"110","author":"Fenelon","year":"2003","journal-title":"Journal of Neural Transmission"},{"issue":"12","key":"10.1002\/14651858.CD007166.pub2-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1002\/mds.21123","article-title":"Employment, medical absenteeism, and disability perception in Parkinson's disease: A pilot double-blind, randomized, placebo-controlled study of entacapone adjunctive therapy","volume":"21","author":"Korchounov","year":"2006","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/mds.21218","article-title":"Placebo-controlled, double-blind dose-finding study of entacapone in fluctuating parkinsonian patients","volume":"22","author":"Mizuno","year":"2007","journal-title":"Movement Disorders"},{"issue":"9463","key":"10.1002\/14651858.CD007166.pub2-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0015|cit15","unstructured":"Brooks DJ Kuoppamaki M Vahteristo M Entacapone decreases axial symptoms and tremor in levodopa-treated Parkinson's disease patients experiencing wearing-off symptoms Movement Disorders 2005 S120 (P405)"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007166.pub2-BIB0016|cit16","first-page":"S42","article-title":"Benefits of COMT inhibitors in levodopa-treated parkinsonian patients. Results of clinical trials","volume":"55","author":"Kieburtz","year":"2000","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0017|cit17","unstructured":"Larsen JP Siden A Worm-Petersen J Gordin A Reinikainen K Kultalahti E-R Long-term efficacy and safety of entacapone in parkinsonian patients with motor fluctuations. An open study of 3 years duration Parkinsonism and Related Disorders 2001 S61 (P-TU-203)"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1468-1331.2003.00559.x","article-title":"The tolerability and efficacy of entacapone over 3 years in patients with Parkinson's disease","volume":"10","author":"Larsen","year":"2003","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0019|cit19","unstructured":"Rinne UK Kieburtz K Reinikainen K Gordin A Effect of entacapone on quality of life related assessments in Parkinson's disease Movement Disorders 2000 135 (P686B)"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1212\/WNL.51.5.1309","article-title":"Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations","volume":"51","author":"Rinne","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0021|cit21","unstructured":"The Nomecomt Study Group Effect of entacapone on factors related to quality of life in Parkinson's disease Movement Disorders 2000 125, 126 (P649)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0022|cit22","unstructured":"The Nomecomt Study Group Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. A 6-month, multicenter, placebo-controlled, double-blind, parallel group study Movement Disorders 1996 267 (SS19)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0023|cit23","unstructured":"Brooks DJ Kuoppamaki M Vahteristo M Entacapone decreases axial symptoms and tremor in levodopa-treated Parkinson's disease patients experiencing wearing-off symptoms Movement Disorders 2005 S120 (P405)"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002826-200109000-00007","article-title":"Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease","volume":"24","author":"Factor","year":"2001","journal-title":"Clinical Neuropharmacology"},{"issue":"Suppl 4","key":"10.1002\/14651858.CD007166.pub2-BIB0025|cit25","first-page":"S42","article-title":"Benefits of COMT inhibitors in levodopa-treated parkinsonian patients. Results of clinical trials","volume":"55","author":"Kieburtz","year":"2000","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1002\/ana.410420511","article-title":"Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients","volume":"42","author":"Parkinson Study Group","year":"1997","journal-title":"Annals of Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0027|cit27","unstructured":"Parkinson Study Group The COMT inhibitor entacapone improves parkinsonian features in fluctuating patients Movement Disorders 1996 268 (SS20)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0028|cit28","unstructured":"Rinne UK Kieburtz K Reinikainen K Gordin A Effect of entacapone on quality of life related assessments in Parkinson's disease Movement Disorders 2000 135 (P686B)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0029|cit29","unstructured":"Im JH Jeon BS Lee MS Lee WY Kim JW Lee MC A multicenter, double-blind, placebo-controlled study to assess efficacy and safety of entacapone in Korean patients with Parkinson's disease experiencing end-of-dose deterioration Movement Disorders 2002 S40 (P83)"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0030|cit30","first-page":"206","article-title":"Efficacy and safety of entacapone in patients with Parkinson's disease experiencing wearing-off phenomenon: Multicenter randomized placebo-controlled double blind study","volume":"23","author":"Im","year":"2005","journal-title":"Journal of the Korean Neurological Society"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0031|cit31","unstructured":"Brooks DJ Kuoppamaki M Vahteristo M Entacapone decreases axial symptoms and tremor in levodopa-treated Parkinson's disease patients experiencing wearing-off symptoms Movement Disorders 2005 S120 (P405)"},{"issue":"8","key":"10.1002\/14651858.CD007166.pub2-BIB0032|cit32","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1136\/jnnp.74.8.1071","article-title":"Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: A randomised, placebo controlled, double-blind, six month study","volume":"74","author":"Brooks","year":"2003","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0033|cit33","unstructured":"Sagar H Brooks D The UK-Irish double-blind study of entacapone in Parkinson's disease Movement Disorders 2000 135 (P686A)"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1017\/S0317167100052598","article-title":"Gait analysis in advanced Parkinson's disease - Effect of levodopa and tolcapone","volume":"28","author":"Shan","year":"2001","journal-title":"The Canadian Journal of Neurological Sciences"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0035|cit35","unstructured":"Shan DE Yek SI A double-blind trial of tolcapone on Chinese patients with Parkinson's disease Movement Disorders 1998 110 (P2.101)"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1136\/jnnp.63.4.421","article-title":"Catechol-O-methyltransferase inhibition with tolcapone reduces the \"wearing-off\" phenomenon and levodopa requirements in fluctuating parkinsonian patients","volume":"63","author":"Baas","year":"1997","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0037|cit37","unstructured":"Ransmayr G Poewe W A multicenter double-blind placebo-controlled study of tolcapone added to levodopa in fluctuating Parkinson's disease Movement Disorders 1996 271 (SS32)"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1212\/WNL.48.1.81","article-title":"Tolcapone improves motor fluctuation and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: A multicenter, double-blind, randomized, placebo-controlled trial","volume":"48","author":"Kurth","year":"1997","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/1531-8257(200005)15:3<497::AID-MDS1012>3.0.CO;2-4","article-title":"Illness impact and adjustment to Parkinson's disease: Before and after treatment with tolcapone","volume":"15","author":"Welsh","year":"2000","journal-title":"Movement Disorders"},{"issue":"8","key":"10.1002\/14651858.CD007166.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1001\/archneur.55.8.1089","article-title":"Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa","volume":"55","author":"Adler","year":"1998","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0041|cit41","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00002826-200109000-00007","article-title":"Long-term comparative experience with tolcapone and entacapone in advanced Parkinson's disease","volume":"24","author":"Factor","year":"2001","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1468-1331.1997.tb00358.x","article-title":"Efficacy and safety of tolcapone in levodopa-treated Parkinson's disease patients with \"wearing-off\" phenomenon: A multicentre, double-blind, randomized, placebo-controlled trial","volume":"4","author":"Myllya","year":"1997","journal-title":"European Journal of Neurology"},{"issue":"6","key":"10.1002\/14651858.CD007166.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1002\/mds.870120615","article-title":"Tolcapone added to levodopa in stable parkinsonian patients: A double-blind placebo-controlled study","volume":"12","author":"Dupont","year":"1997","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1212\/WNL.49.4.1066","article-title":"Tolcapone improves motor function in parkinsonian patients with the \"wearing-off\" phenomenon: A double-blind, placebo-controlled, multicenter trial","volume":"49","author":"Rajput","year":"1997","journal-title":"Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1055\/s-2008-1069894","article-title":"Bromocriptine in the treatment of progressive stages of Parkinson's disease","volume":"107","author":"Schneider","year":"1982","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1111\/j.1600-0404.1985.tb00858.x","article-title":"Effects of bromocriptine on Parkinsonism. A nation-wide collaborative double-blind study","volume":"72","author":"Toyokura","year":"1985","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000114930","article-title":"Bromocryptine in levodopa response-losing parkinsonism. A double-blind study","volume":"17","author":"Jansen","year":"1978","journal-title":"European Neurology"},{"issue":"11","key":"10.1002\/14651858.CD007166.pub2-BIB0048|cit48","first-page":"680","article-title":"Adjunctive therapy with bromocriptine in Parkinson's disease","volume":"78","author":"Temlett","year":"1990","journal-title":"South African Medical Journal"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0049|cit49","unstructured":"Miguel F Obeso JA Olive Plana JM Tolosa E Villanueva Eusa JA Dubini A Double-blind parallel group study of the efficacy and tolerability of cabergoline vs. placebo in parkinsonian patients with motor fluctuation Confidential Report 1993"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1007\/BF00878534","article-title":"Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations","volume":"243","author":"Steiger","year":"1996","journal-title":"Journal of Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0051|cit51","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1212\/WNL.46.4.1062","article-title":"Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease","volume":"46","author":"Hutton","year":"1996","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0052|cit52","unstructured":"Lieberman AN Hutton JT Levodopa sparing effect of cabergoline compared to placebo in patients affected by motor fluctuations, under levodopa therapy Movement Disorders 1996 269 (SS25)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0053|cit53","unstructured":"Schoenfelder J Simons J Souder DE Bianchine J A placebo-controlled study of the safety and efficacy of cabergoline in the treatment of Parkinson's disease FCE Report: 21336\/731i, Clinical Reference 42 1993"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0054|cit54","unstructured":"Musch B Bonura L The Investigator Study Group Cabergoline once a day as adjunctive therapy to levodopa in Parkinson's disease Movement Disorders 2000 (P632)"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1002\/mds.870090107","article-title":"A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's Disease","volume":"9","author":"Olanow","year":"1994","journal-title":"Movement Disorders"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1136\/jnnp.66.4.436","article-title":"Efficacy, safety and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: A double blind, placebo controlled, randomised, multicentre study","volume":"66","author":"Pinter","year":"1999","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD007166.pub2-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1468-1331.1998.530235.x","article-title":"A double-blind, placebo-controlled, randomized, multi-center study of pramipexole in advanced Parkinson's disease","volume":"5","author":"Wermuth L and the Danish Pramipexole Study Group","year":"1998","journal-title":"European Journal of Neurology"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0059|cit59","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/mds.20397","article-title":"Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: Results from a European multicenter trial","volume":"20","author":"Carsten Moller","year":"2005","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0060|cit60","first-page":"301","article-title":"Pramipexole, a nonergot dopamine agonist, is effective against rest tremor in intermediate to advanced Parkinson's disease","volume":"22","author":"Kunig","year":"1999","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/S0022-510X(03)00217-X","article-title":"Efficacy, safety, and tolerability of pramipexole in untreated and levodopa-treated patients with Parkinson's disease","volume":"216","author":"Wong","year":"2003","journal-title":"Journal of the Neurological Sciences"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1212\/WNL.49.1.162","article-title":"Clinical evaluation of pramipexole in advanced Parkinson's disease: Results of a double-blind, placebo-controlled, parallel-group study","volume":"49","author":"Lieberman","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1353-8020(00)00031-6","article-title":"The long-term safety and efficacy of pramipexole in advanced Parkinson's disease","volume":"7","author":"Weiner","year":"2001","journal-title":"Parkinsonism and Related Disorders"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1212\/WNL.49.4.1060","article-title":"Double-blind comparison of pramipexole and bromocriptine treatment with placebo in advanced Parkinson's disease","volume":"49","author":"Guttman M and the International Pramipexole-Bromocriptine Study Group","year":"1997","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0065|cit65","unstructured":"Pahwa R Stacy MA Elmer LW Isaacson SH Ropinirole 24-hour prolonged release provides efficacy as early as week 2 when used as adjunctive therapy to L-dopa in patients with advanced Parkinson's disease Movement Disorders 2006 S595 (P968)"},{"issue":"14","key":"10.1002\/14651858.CD007166.pub2-BIB0066|cit66","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1212\/01.wnl.0000258660.74391.c1","article-title":"Ropinirole 24-hour prolonged release: Randomised, controlled study in advanced Parkinson disease","volume":"68","author":"Pahwa","year":"2007","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0067|cit67","unstructured":"Sethi KD Hauser RA Earl NL Ropinirole 24-hour prolonged release improves disease-specific and global symptoms when used as adjunctive therapy to L-dopa in patients with advanced Parkinson's disease Movement Disorders 2006 S570 (P887)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0068|cit68","unstructured":"Sethi KD Stocchi F Giorgi L Ropinirole 24-hour prolonged release in advanced Parkinson's disease: Relationship between treatment response and disease severity Movement Disorders 2007 S92 (301)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0069|cit69","unstructured":"Stacy MA Pahwa R Earl NL Ropinirole 24-hour prolonged release reduces \"off\" time and the dose of L-dopa needed when used as adjunctive therapy in patients with advanced Parkinson's disease Movement Disorders 2006 S596 (P972)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0070|cit70","unstructured":"Stocchi F Hersh BP Earl NL Scott BL Safety and tolerability of ropinirole 24-hour prolonged release in patients with early and advanced Parkinson's disease Movement Disorders 2006 S572 (P894)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0071|cit71","unstructured":"Stocchi F Stover NP Giorgi L Ropinirole 24-hour prolonged release as adjunct to L-dopa in patients with advanced Parkinson's disease - efficacy according to baseline depression score Movement Disorders 2007 S90 (295)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0072|cit72","first-page":"531","article-title":"A placebo-controlled study of ropinirole, a new D2 agonist, in the treatment of motor fluctuations of L-dopa-treated parkinsonian patients","volume-title":"Advances in Neurology","volume":"69","author":"Rascol","year":"1996"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/00002826-199619030-00005","article-title":"Ropinirole in the treatment of levodopa-induced motor fluctuations in patients with Parkinson's disease","volume":"19","author":"Rascol","year":"1996","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0074|cit74","unstructured":"Korczyn Anti-Parkinson efficacy (L-dopa sparing effect) of ropinirole versus placebo as adjunct therapy in parkinsonian patients not optimally controlled on L-dopa Confidential Report 1990"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0075|cit75","unstructured":"Kreider M Knox S Gardiner D Wheadon D A multicenter double-blind study of ropinirole as an adjunct to L-dopa in Parkinson's disease Neurology 1996 A475 (S67.003)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0076|cit76","unstructured":"Kreider MS Knox S Gardiner D Wheadon D The efficacy of ropinirole, a non-ergoline D2 agonist, as an adjunct to L-dopa (DCI) in patients with Parkinson's disease Movement Disorders 1996 156 (P577)"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1212\/WNL.51.4.1057","article-title":"A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease","volume":"51","author":"Lieberman","year":"1998","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0078|cit78","unstructured":"Rabey JM Sagi I Huberman M Melamed E Korczyn A Giladi N Inzelberg R Djaldetti R Klein C Berecz G and the Rasagiline Study Group Rasagiline mesylate, a new MAO-B Inhibitor for treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa Movement Disorders 1998 148 (P2.254)"},{"issue":"6","key":"10.1002\/14651858.CD007166.pub2-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1097\/00002826-200011000-00005","article-title":"Rasagiline Mesylate, a new Mao-B inhibitor for the treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa","volume":"23","author":"Rabey","year":"2000","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0080|cit80","unstructured":"Rabey JM Sagi I Huberman M Melamed E. The Rasagiline Study Group Rasagiline Mesylate, a new MAO-B Inhibitor for treatment of Parkinson's disease: A double-blind study as adjunctive therapy to levodopa Parkinsonism and Related Disorders 2001 S66-S67 (P-TU-224)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0081|cit81","unstructured":"Fernandez H Rasagiline adjunct therapy produces marked levels of response across all Parkinson's disease severities: Pooled data analysis from the PRESTO and LARGO studies Movement Disorders 2006 S494 (P613)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0082|cit82","unstructured":"Rabey JM Fitzer-Attas CJ Effect of adjunct rasagiline on dopaminergic and non-dopaminergic motor features of Parkinson's disease Movement Disorders 2007 S92 (300)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0084|cit83","unstructured":"Rascol O Brooks DJ Melamed E Oertel W Poewe W Stocchi F Tolosa E The role of rasagiline in the complex treatment of moderate to advanced Parkinson's disease Parkinsonism and Related Disorders 2005 263 (IS004-04)"},{"issue":"9463","key":"10.1002\/14651858.CD007166.pub2-BIB0083|cit84","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/S0140-6736(05)71083-7","article-title":"Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): A randomised, double-blind, parallel-group trial","volume":"365","author":"Rascol","year":"2005","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0085|cit85","unstructured":"Tolosa E Rasagiline is efficacious and safe in the treatment of elderly patients (>=70 years) with Parkinson's disease (PD): Pooled data analysis Movement Disorders 2006 S579 (P916)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0086|cit86","unstructured":"Elmer L Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctations receiving other adjunctive therapy Movement Disorders 2005 S138 (P468)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0087|cit87","unstructured":"Fernandez H Rasagiline adjunct therapy produces marked levels of response across all Parkinson's disease severities: Pooled data analysis from the PRESTO and LARGO studies Movement Disorders 2006 S494 (P613)"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0088|cit88","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1001\/archneur.62.2.241","article-title":"A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson's disease and motor fluctuations. The PRESTO Study Group","volume":"62","author":"Parkinson Study Group","year":"2005","journal-title":"Archives of Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0089|cit89","unstructured":"Rascol O Brooks DJ Melamed E Oertel W Poewe W Stocchi F Tolosa E The role of rasagiline in the complex treatment of moderate to advanced Parkinson's disease Parkinsonism and Related Disorders 2005 263 (IS004-04)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0090|cit90","unstructured":"Tolosa E Rasagiline is efficacious and safe in the treatment of elderly patients (>=70 years) with Parkinson's disease (PD): Pooled data analysis Movement Disorders 2006 S579 (P916)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0091|cit91","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1111\/j.1600-0404.1983.tb01527.x","article-title":"Deprenyl (selegiline) combined with levodopa and a decarboxylase inhibitor in the treatment of Parkinson's disease","volume":"Supplement 95","author":"Presthus","year":"1983","journal-title":"Acta Neurologica Scandinavica"},{"issue":"Supplement","key":"10.1002\/14651858.CD007166.pub2-BIB0092|cit92","first-page":"123","article-title":"Double-blind trial of R-(-)-deprenyl for the 'on-off' effect complicating Parkinson's disease","volume":"25","author":"Golbe","year":"1987","journal-title":"Journal of Neural Transmission"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0093|cit93","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00002826-198802000-00004","article-title":"Deprenyl in the treatment of symptom fluctuations in advanced Parkinson's disease","volume":"11","author":"Golbe","year":"1988","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0094|cit94","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1002\/mds.20036","article-title":"Zydis Selegiline reduces off time in Parkinson's disease patients with motor fluctations: A 3-month, randomized, placebo-controlled study","volume":"19","author":"Waters","year":"2004","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0095|cit95","unstructured":"Shellenberger MK Clarke A Donoghue S Zydis selegiline reduces 'off' time and improves symptoms in patients with Parkinson's disease Movement Disorders 2000 (P616)"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0096|cit96","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00002826-200105000-00006","article-title":"The effects of different repeated doses of entacapone on the pharmacokinetics of L-dopa and on the clinical responses to L-Dopa in Parkinson's disease","volume":"24","author":"Heikkinen","year":"2001","journal-title":"Clinical Neuropharmacology"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0098|cit97","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1097\/00002826-199619040-00001","article-title":"A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjunct to levodopa therapy in advanced Parkinson's disease","volume":"19","author":"Ruottinen","year":"1996","journal-title":"Clinical Neuropharmacology"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0099|cit98","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/jnnp.60.1.36","article-title":"Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations","volume":"60","author":"Ruottinen","year":"1996","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0097|cit99","unstructured":"Ruottinen HM Rinne UK Vakeva M Gordin A Prolonged motor response to each L-dopa dose after entacapone administration is reflected as increased total daily 'on' time in parkinsonian patients with fluctuations Movement Disorders 1996 195 (P732)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0100|cit100","unstructured":"Lyytinen J Kaakkola S Teravainen H Sovijarvi A Kultalahti ER Gordin A The effect of COMT inhibition with entacapone on cardiovascular exercise capacity and haemodynamics in levodopa-treated patients with Parkinson's disease Parkinsonism and Related Disorders 2001 S62 (P-TU-207)"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0101|cit101","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1097\/00002826-200101000-00009","article-title":"The effect of catechol-O-methyltransferase inhibition with entacapone on cardiovascular autonomic responses in L-dopa-treated patients with Parkinson's disease","volume":"24","author":"Lyytinen","year":"2001","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0102|cit102","unstructured":"Barbato L Nordera G Bolner A Caraceni T Stocchi F Entacapone increases the bioavailability of controlled-release L-dopa and prolongs on time in patients with Parkinson's disease (PD) Movement Disorders 2002 S45 (P101)"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0103|cit103","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s00702-003-0092-9","article-title":"Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa\/carbidopa in Parkinson's patients","volume":"111","author":"Stocchi","year":"2004","journal-title":"Journal of Neural Transmission"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0105|cit104","unstructured":"Merello M Lees AJ The effect of the novel catechol-O-methyltransferase inhibitor OR-611 on the clinical response to levodopa Movement Disorders 1992 102 (P285B)"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0104|cit105","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.57.2.186","article-title":"Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson's disease","volume":"57","author":"Merello","year":"1994","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0106|cit106","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1136\/jnnp.68.5.589","article-title":"The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease","volume":"68","author":"Piccini","year":"2000","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0107|cit107","unstructured":"Ferreira JJ Cunha L Ticmeanu M Roas MM Januario C Mitu C Coelho M Machado C Novac M Correia-Guedes L Morgadinho A Tanasescu R Mihailescu G Falcao A Nunes T Almeida P Soares-da-Silva P Movement Disorders 2006 S644 S645"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0108|cit108","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/00002826-200003000-00007","article-title":"Clinical, pharmacokinetic, and pharmacodynamic effects of tolcapone withdrawal in levodopa-treated patients with parkinsonism","volume":"23","author":"Jorga","year":"2000","journal-title":"Clinical Neuropharmacology"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0109|cit109","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archneur.58.2.249","article-title":"Induction by dopamine D1 receptor agonist ABT-431 of dyskinesia similar to levodopa in patients with Parkinson disease","volume":"58","author":"Rascol","year":"2001","journal-title":"Archives of Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0110|cit110","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1111\/j.1600-0404.1977.tb01433.x","article-title":"Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease","volume":"56","author":"Gron","year":"1977","journal-title":"Acta Neurologica Scandinavica"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0111|cit111","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1212\/WNL.35.2.199","article-title":"Low dosages of bromocriptine added to levodopa in Parkinson's disease","volume":"35","author":"Hoehn","year":"1985","journal-title":"Neurology"},{"issue":"12","key":"10.1002\/14651858.CD007166.pub2-BIB0112|cit112","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1136\/jnnp.41.12.1109","article-title":"Treatment of the on-off syndrome in parkinsonism with low dose bromocriptine in combination with levodopa","volume":"41","author":"Bateman","year":"1978","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"7980","key":"10.1002\/14651858.CD007166.pub2-BIB0113|cit113","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S0140-6736(76)90728-5","article-title":"Bromocriptine and levodopa (with or without carbidopa) in parkinsonism","volume":"2","author":"Kartzinel","year":"1976","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007166.pub2-BIB0114|cit114","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1159\/000116865","article-title":"Nation-wide collaborative study on the long-term effects of bromocriptine in the treatment of Parkinsonian patients: Final Report","volume":"32","author":"Nakanishi","year":"1992","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007166.pub2-BIB0115|cit115","first-page":"3","article-title":"A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease: First interim report in Japan","volume":"28","author":"Nakanishi","year":"1988","journal-title":"European Journal of Neurology"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007166.pub2-BIB0116|cit116","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000116716","article-title":"A nationwide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease: The fourth interim report","volume":"31","author":"Nakanishi","year":"1991","journal-title":"European Journal of Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0117|cit117","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1212\/WNL.26.6.511","article-title":"Studies with bromocriptine part 2. Double-blind comparison with levodopa in idiopathic parkinsonism","volume":"26","author":"Kartzinel","year":"1976","journal-title":"Neurology"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0118|cit118","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00002826-199619030-00002","article-title":"Adjunctive cabergoline therapy of Parkinson's disease: Comparison with placebo and assessment of dose responses and duration of effect","volume":"19","author":"Ahlskog","year":"1996","journal-title":"Clinical Neuropharmacology"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0119|cit119","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1212\/WNL.37.5.863","article-title":"Advanced Parkinson's disease: Use of partial dopamine agonist, ciladopa","volume":"37","author":"Lieberman","year":"1987","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0120|cit120","unstructured":"Xiao A Zhang B Chen Y A placebo-controlled evaluation of pergolide mesylate as combined dopaminergic therapy in advanced Parkinson's disease Journal of Neural Transmission 1999 XXXVII"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0121|cit121","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1212\/WNL.35.3.291","article-title":"Double-blind trial of pergolide for Parkinson's disease","volume":"35","author":"Diamond","year":"1985","journal-title":"Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0122|cit122","first-page":"555","article-title":"Double-blind controlled study of pergolide mesylate as an adjunct to sinemet in the treatment of Parkinson's disease","volume":"45","author":"Olanow","year":"1987","journal-title":"Advances in Neurology"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0123|cit123","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1097\/00002826-198704000-00009","article-title":"Double-blind controlled study of pergolide mesylate in the treatment of Parkinson's disease","volume":"10","author":"Olanow","year":"1987","journal-title":"Clinical Neuropharmacology"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0124|cit124","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00002826-198509000-00006","article-title":"Pergolide therapy in Parkinson's Disease: A double-blind, placebo-controlled study","volume":"8","author":"Sage","year":"1985","journal-title":"Clinical Neuropharmacology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0125|cit125","first-page":"551","article-title":"Parallel double-blind study of pergolide in Parkinson's disease","volume":"45","author":"Jankovic","year":"1986","journal-title":"Advances in Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0126|cit126","unstructured":"Fedorova N Jamrozik Z Takacs A Ruzicka E Del Signore S Kwiecinski H Safety and efficacy of piribedil as adjunctive treatment for Parkinson's disease: Six month placebo-controlled study Movement Disorders 2002 S101 (P295)"},{"issue":"7","key":"10.1002\/14651858.CD007166.pub2-BIB0127|cit127","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/mds.20400","article-title":"End-of-dose akinesia after a single intravenous infusion of the dopaminergic agonist piribedil in Parkinson's disease patients: A pharmacokinetic\/pharmacodynamic, randomized, double-blind study","volume":"20","author":"Simon","year":"2005","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0128|cit128","unstructured":"Salazar G Cardiel C Rheder P Jimenez JC Piribedil in adjunction to L-dopa in Parkinson's disease patients: A 9-month follow up Movement Disorders 2002 S47 (P108)"},{"issue":"8","key":"10.1002\/14651858.CD007166.pub2-BIB0129|cit129","first-page":"715","article-title":"The effectiveness and tolerance of piribedil as adjunct therapy to levodopa in patients with Parkinson's disease : A nine-month follow-up (Spanish)","volume":"38","author":"Salazar-Tortolero","year":"2004","journal-title":"Revista de Neurologia"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0130|cit130","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/1531-8257(199903)14:2<336::AID-MDS1021>3.0.CO;2-9","article-title":"A randomized, double-blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease","volume":"14","author":"Montastruc","year":"1999","journal-title":"Movement Disorders"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0131|cit131","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1097\/01.wnf.0000240943.59617.4c","article-title":"Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage","volume":"30","author":"Parkinson Study Group","year":"2007","journal-title":"Clinical Neuropharmacology"},{"issue":"Suppl","key":"10.1002\/14651858.CD007166.pub2-BIB0132|cit132","first-page":"225","article-title":"The use of pramipexole, a novel dopamine (DA) agonist, in advanced Parkinson's disease","volume":"45","author":"Molho","year":"1995","journal-title":"Journal of Neural Transmission"},{"issue":"10","key":"10.1002\/14651858.CD007166.pub2-BIB0133|cit133","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/mds.10508","article-title":"Randomised, double-blind study of pramipexole with placebo and bromocriptine in advanced Parkinson's disease","volume":"18","author":"Mizuno","year":"2003","journal-title":"Movement Disorders"},{"issue":"6","key":"10.1002\/14651858.CD007166.pub2-BIB0134|cit134","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S1474-4422(07)70108-4","article-title":"Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: A double-blind, double-dummy, randomised controlled trial","volume":"6","author":"Poewe","year":"2007","journal-title":"Lancet Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0135|cit135","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1600-0404.1978.tb02862.x","article-title":"Dopaminergic agonist Ro 8-4650 in Parkinson's disease. I. Patients treated with dopa","volume":"58","author":"Birket-Smith","year":"1978","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0136|cit136","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1212\/01.wnl.0000259516.61938.bb","article-title":"Advanced Parkinson's disease treated with rotigotine transdermal system. PREFER Study","volume":"68","author":"LeWitt","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0137|cit137","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/mds.870080408","article-title":"Terguride in fluctuating Parkinsonian patients: a double-blind study versus placebo","volume":"8","author":"Pacchetti","year":"1993","journal-title":"Movement Disorders"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0138|cit138","unstructured":"Teychenne PF Heinonen ESA Double-blind dose-response study of selegiline as an adjuvant to levodopa and bromocriptine in patients with Parkinson's disease Movement Disorders 1994 71 (P301)"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0139|cit139","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0404.1989.tb01791.x","article-title":"Double-blind, crossover placebo controlled trial of selegiline in Parkinson's disease - an interim analysis","volume":"126","author":"Teychenne","year":"1989","journal-title":"Acta Neurologica Scandinavica"},{"issue":"6","key":"10.1002\/14651858.CD007166.pub2-BIB0140|cit140","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1111\/j.1600-0404.1985.tb03233.x","article-title":"The effect of L-Deprenyl on on-off phenomena in Parkinson's disease","volume":"71","author":"Brodersen","year":"1985","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0141|cit141","first-page":"113","article-title":"Selegiline in the treatment of daily fluctuations in disability of parkinsonian patients with long-term levodopa treatment","volume":"126","author":"Heinonen","year":"1989","journal-title":"Acta Neurologica Scandinavica"},{"issue":"9","key":"10.1002\/14651858.CD007166.pub2-BIB0142|cit142","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1212\/WNL.38.9.1387","article-title":"Two weeks of treatment with deprenyl (selegiline) does not prolong L-dopa effect in parkinsonian patients: A double-blind cross-over placebo-controlled trial","volume":"38","author":"Rascol","year":"1988","journal-title":"Neurology"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0143|cit143","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1097\/00002826-199302000-00010","article-title":"Effects of selegiline dosing on motor fluctuations in Parkinson's disease","volume":"16","author":"Hubble","year":"1993","journal-title":"Clinical Neuropharmacology"},{"issue":"3-4","key":"10.1002\/14651858.CD007166.pub2-BIB0144|cit144","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/BF01246961","article-title":"Recent observations on the clinical pharmacology of deprenyl","volume":"43","author":"Stern","year":"1978","journal-title":"Journal of Neural Transmission"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0145|cit145","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1097\/00002826-198910000-00010","article-title":"A double-blind, controlled study of high-dose L-Deprenyl in the treatment of Parkinson's disease","volume":"12","author":"Frankel","year":"1989","journal-title":"Clinical Neuropharmacology"},{"issue":"12","key":"10.1002\/14651858.CD007166.pub2-BIB0146|cit146","first-page":"646","article-title":"Deprenyl versus placebo in Parkinson disease: A double-blind study","volume":"87","author":"Lieberman","year":"1987","journal-title":"New York State Journal of Medicine"},{"issue":"8042","key":"10.1002\/14651858.CD007166.pub2-BIB0147|cit147","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/S0140-6736(77)90725-5","article-title":"Deprenyl in Parkinson's disease","volume":"2","author":"Lees","year":"1977","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0148|cit148","unstructured":"PD MED Ongoing study November 2000"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0149|cit149","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/S0140-6736(00)02039-0","article-title":"Subgroup analysis and other (mis)uses of baseline data in clinical trials","volume":"355","author":"Assmann","year":"2000","journal-title":"Lancet"},{"issue":"11","key":"10.1002\/14651858.CD007166.pub2-BIB0150|cit150","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1002\/mds.21473","article-title":"Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off","volume":"22","author":"Deuschl","year":"2007","journal-title":"Movement Disorders"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0151|cit151","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001518","article-title":"Lisuride for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0152|cit152","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000235","article-title":"Pergolide for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"1999","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD007166.pub2-BIB0153|cit153","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002261","article-title":"Pramipexole for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0154|cit154","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1111\/j.1742-1241.2001.tb11025.x","article-title":"DICE 2: A further investigation of the effect of chance in life, death and subgroup analyses","volume":"55","author":"Clarke","year":"2001","journal-title":"International Journal of Clinical Practice"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0155|cit155","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001518","article-title":"Cabergoline for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0156|cit156","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001516","article-title":"Ropinirole for levodopa-induced complications in Parkinson's disease","author":"Clarke","year":"2001","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"Suppl 1","key":"10.1002\/14651858.CD007166.pub2-BIB0157|cit157","doi-asserted-by":"crossref","first-page":"I22","DOI":"10.1136\/jnnp.72.suppl_1.i22","article-title":"Medical management of Parkinson's disease","volume":"72","author":"Clarke","year":"2002","journal-title":"Journal of Neurology, Neurosurgery and Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD007166.pub2-BIB0158|cit158","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004554.pub2","article-title":"Catechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson's disease","author":"Deane","year":"2004","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0159|cit159","doi-asserted-by":"crossref","DOI":"10.1002\/9780470693926.ch15","article-title":"Statistical methods for examining heterogeneity and combining results from several studies in meta-analysis","volume-title":"Systematic Reviews in Health Care: Meta-analysis in Context","author":"Deeks","year":"2001"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0160|cit160","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/bmj.309.6964.1286","article-title":"Identifying relevant studies for systematic reviews","volume":"309","author":"Dickersin","year":"1994","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0161|cit161","volume-title":"Treatment of Early Breast Cancer. Vol 1. Worldwide Evidence 1985-1990","author":"Early Breast Cancer Trialists' Collaborative Group","year":"1990"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0162|cit162","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1177\/096228029300200202","article-title":"The statistical basis of meta-analysis","volume":"2","author":"Fleiss","year":"1993","journal-title":"Statistical Methods in Medical Research"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0163|cit163","first-page":"719","article-title":"Statistical aspects of the analysis of data from retrospective studies of disease","volume":"22","author":"Mantel","year":"1959","journal-title":"National Cancer Institute Journal"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0164|cit164","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1002\/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8","article-title":"Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints","volume":"17","author":"Parmar","year":"1998","journal-title":"Statistics in Medicine"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0165|cit165","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bjc.1977.1","article-title":"Design and analysis of randomised clinical trials requiring prolonged observation of each patient. II. analysis and examples","volume":"35","author":"Peto","year":"1977","journal-title":"British Journal of Cancer"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0166|cit166","first-page":"1","article-title":"Parkinson's disease: clinical features","volume":"6","author":"Quinn","year":"1997","journal-title":"Bailli\u00e8res Clinical Neurology"},{"key":"10.1002\/14651858.CD007166.pub2-BIB0167|cit167","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/bmj.318.7179.311","article-title":"Science, medicine and the future: Parkinson's disease","volume":"318","author":"Scharipa","year":"1999","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD007166.pub2-BIB0168|cit168","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1002\/1531-8257(199901)14:1<38::AID-MDS1008>3.0.CO;2-I","article-title":"Efficacy and tolerability of tolcapone compared with bromocriptine in levodopa-treated parkinsonian patients","volume":"14","author":"The Tolcapone Study Group","year":"1999","journal-title":"Movement Disorders"},{"issue":"5","key":"10.1002\/14651858.CD007166.pub2-BIB0169|cit169","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/mds.1175","article-title":"Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.","volume":"16","author":"Koller","year":"2001","journal-title":"Movement Disorders"},{"issue":"3","key":"10.1002\/14651858.CD007166.pub2-BIB0170|cit170","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD001203","article-title":"Bromocriptine for levodopa-induced motor complications in Parkinson's disease","author":"Hilten","year":"1998","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD007166.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,26]],"date-time":"2026-01-26T00:03:41Z","timestamp":1769385821000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD007166.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Movement Disorders Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2010,7,7]]},"references-count":170,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2010,7]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd007166.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7,7]]}}}